AB

ABION Inc.

Clinical-stage biopharma developing therapeutics for oncology and viral diseases.

203400 | KO

Overview

Corporate Details

ISIN(s):
KR7203400007
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 242 한화비즈메트로1차 242915호, 서울특별시

Description

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-10 00:00
주식등의대량보유상황보고서(약식)
Korean 69.0 KB
2025-07-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.2 KB
2025-07-04 00:00
주식등의대량보유상황보고서(일반)
Korean 133.0 KB
2025-07-04 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 33.2 KB
2025-06-27 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 37.9 KB
2025-06-25 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-06-24 00:00
투자판단관련주요경영사항 (ABN501 공동개발 및 라이선스 계약 체결)
Korean 10.4 KB
2025-06-13 00:00
주식등의대량보유상황보고서(일반)
Korean 133.4 KB
2025-06-11 00:00
최대주주변경을수반하는주식담보제공계약체결
Korean 31.5 KB
2025-06-05 00:00
주식등의대량보유상황보고서(일반)
Korean 133.4 KB
2025-05-30 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-02 00:00
주식등의대량보유상황보고서(약식)
Korean 67.5 KB
2025-04-25 00:00
주식등의대량보유상황보고서(일반)
Korean 133.4 KB
2025-04-11 00:00
주식등의대량보유상황보고서(일반)
Korean 135.3 KB

Automate Your Workflow. Get a real-time feed of all ABION Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ABION Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ABION Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG
Adaptive Biotechnologies Corp Logo
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
United States of America
ADPT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.